← All trials
NCT05727839
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 24, 2023
- Primary completion
- Jul 24, 2025
- Completion date
- Aug 24, 2025
- First posted
- Feb 14, 2023
- Last posted
- Mar 20, 2023
- Enrollment
- 156
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Immorna Biotherapeutics, Inc.Lead sponsor
- Sun Yat-Sen UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.